Quibim Enhances Flagship QP Prostate Product with The Launch of AI-QUAL^TM: Industry-First AI Tool for Automated Prostate MRI Image Quality Assessment Based on PI-QUAL

• New AI-QUAL^TM feature enhances Quibim’s flagship QP-Prostate^® platform, which uses biopsy and MRI data for training, with automated image quality scoring based on PI-QUAL v2 guidelines 

• Tool aims to standardize prostate MRI quality assessment and reduce diagnostic variability

26 June 2025 – Quibim, a global leader in quantitative medical imaging solutions, announces the launch of AI-QUAL^TM, a pioneering new feature to Quibim’s flagship QP-Prostate platform, that automates the assessment of prostate MRI image quality in accordance with the PI-QUAL v2 guidelines. This innovation marks a significant step forward in standardizing prostate MRI quality, enhancing diagnostic confidence, and streamlining radiology workflows. 

AI-QUAL^TM leverages advanced artificial intelligence to evaluate prostate MRI studies and assign a standardized score from 1 to 3, reflecting the diagnostic quality of the images. The system automatically detects common artifacts—such as rectal gas distortion and metal interference—that can compromise image quality and reduce diagnostic accuracy. 

Recent studies have shown that one in three prostate MRI scans in the US are not of diagnostic quality, underscoring the urgent need for automated, objective quality control tools in prostate imaging. 

Key benefits of AI-QUAL^TM include: 

• Automated Quality Scoring: Eliminates manual checks, saving time and reducing subjectivity 

• Standardized Reporting: Delivers consistent quality score based on PI-QUAL v2 guidelines 

• Artifact Detection: Identifies key image-degrading factors such as rectal gas distortion and metal artifacts 

• Diagnostic Confidence: Ensures radiologists work with the highest quality images 

• Seamless Integration: Designed to fit effortlessly into existing radiology workflows 

David Bazaga, VP of Product at Quibim, commented: “AI-QUAL^TM represents a major advancement in our mission to transform imaging into a driver of precision health. By automating image quality assessment, we’re helping radiologists reduce variability, improve diagnostic accuracy, and ultimately deliver better outcomes for patients.” 

Low-quality imaging has been linked to an increase in PI-RADS 3 findings, which can lead to unnecessary biopsies and negatively impact patient care. AI-QUAL^TM addresses this challenge by providing a standardized, automated approach to image quality assessment, helping clinicians make more confident and informed decisions. 

Dr. Ángel Alberich-Bayarri, CEO and Founder of Quibim, added: “We are proud to introduce AI-QUAL^TM as part of our growing suite of prostate imaging solutions. This tool directly addresses a critical gap in prostate MRI quality control and reinforces our commitment to supporting radiologists with cutting-edge, clinically validated AI technologies.” 

AI-QUAL^TM is now available as part of Quibim’s QP-Prostate^® platform, further strengthening its position as a comprehensive solution for prostate cancer detection, diagnosis, and care. 

About Quibim 

Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York (United States), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 190 sites are using Quibim products globally.  

To learn more about Quibim visit https://quibim.com/, and follow us on X and LinkedIn.